A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (NCT06663319)
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
Who can join: Review the eligibility criteria below.
Location: University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of Arizona Cancer Center — Tucson, Arizona
- University of Colorado Denver Anschultz Medical Campus — Aurora, Colorado
- Florida Cancer Specialists — Sarasota, Florida
- Community Health Network — Indianapolis, Indiana
- Start Midwest — Grand Rapids, Michigan
- Swedish Cancer Institute — Seattle, Washington
- Severance Hospital Yonsei University Health System — Seoul,
- Asan Medical Center — Seoul,
- Hosp Univ Vall D Hebron — Barcelona,
- Hosp Univ Fund Jimenez Diaz — Madrid,
- Hosp. Univ. 12 de Octubre — Madrid,
- Hosp Univ Hm Sanchinarro — Madrid,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Neoplasms
- S0820, Adenoma and Second Primary Prevention Trial — Birmingham, Alabama
- MyGI Diet for Colorectal Cancer Prevention — Ann Arbor, Michigan
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer — Gilbert, Arizona
- Combination Immunotherapy in Colorectal Cancer — Brooklyn, New York
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Encinitas, California
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... — Bethesda, Maryland
Explore by condition: All Colorectal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.